- View All Journals
- Expert Opinion on
- Expert Review of
- Anticancer Therapy
- Anti-infective Therapy
- Cardiovascular Therapy
- Clinical Immunology
- Clinical Pharmacology
- Endocrinology & Metabolism
- Gastroenterology & Hepatology
- Medical Devices
- Molecular Diagnostics
- Obstetrics & Gynecology
- Pharmacoeconomics & Outcomes Research
- Respiratory Medicine
- Current Medical Research and Opinion
- Journal of Medical Economics
- Journal of Drug Assessment
- View All Books
- View Book Series
- Basic and Clinical Dermatology
- BioMed Tracker Reports
- Clinical and Basic Science Dermatology
- Cosmetic Science and Technology
- Drugs and the Pharmaceutical Sciences
- European Society of Medical Oncology
- Fundamental and Clinical Cardiology
- Infectious Disease and Therapy
- Lung Biology in Health and Disease
- Medical Psychiatry
- Reproductive Medicine/Assisted Tech
- Series in Cosmetic and Laser Therapy
- Series in Dermatological Treatment
- Series in Maternal-fetal Medicine
- Target Organ Toxicology
- Translational Medicine
- Encyclopedias and Reference Works
- Expert Opinion on Cardiovascular Disease
- Expert Opinion on Haematology
- Expert Opinion on Infection
- Expert Opinion on Musculoskeletal Disorders
- Expert Opinion on Neurology
- Expert Opinion on Oncology
- Expert Opinion on Psychiatry
- Expert Opinion on Respiratory Disease
- Informa Healthcare Diabetes Collection
Expert Opinion on Therapeutic Patents
About the Journal
Editor in Chief: Claudiu T Supuran, University of Florence, Italy
Commissioning Editor: Emma Luscombe
2012 ISI Impact Factor: 3.525
ISSN: 1354-3776 (print), 1744-7674 (electronic)
- The use of salt-inducible kinase inhibitors to treat autoimmune and inflammatory diseases: evaluation of WO2013136070
- Novel thiazole derivatives: a patent review (2008 – 2012. Part 2)
- LEDGINs, non-catalytic site inhibitors of HIV-1 integrase: a patent review (2006 – 2022)
Marc De Maeyer,
- A patent review on the development of human cytochrome P450 inhibitors
- Retiferols – synthesis and biological activity of a conceptually novel class of vitamin D analogs
Narasimha Rao Bolla,
April 22, 2022Carbonic anhydrase inhibitors (CAIs) have been a particularly hot topic recently, with a comprehensive review of the safety aspects associated with these drugs when used to treat different diseases published in Expert Opinion on Drug Safety in the April issue.
March 26, 2022Claudiu Supuran picks Small-molecule inhibitors of histone deacetylase for the treatment of cancer and non-cancer diseases: a patent review (2011 – 2013) by Sergio Valente & Antonello Mai as the highlight of the April issue. Read it FREE here.
March 10, 2022Fungal infections represent a worldwide health problem and resistance to many of the clinically used drugs is reported more and more frequently. The review presents a discussion of the patent literature in the last three years, with a focus on compounds with broad efficacy, good pharmacologic profiles, absence of drug-drug interactions, etc. Click HERE to read.
February 17, 2022First-in-Class drugs and their novel mechanisms of action are the focus of the first Expert Opinion and Expert ReviewsCross-series themed issue. All articles will be published in their respective journals between January and April 2022 so half of them are already available!
February 10, 2022The Editor-in-Chief of Expert Opinion on Therapeutic Patents, Claudiu Supuran, has chosen Novel thiazole derivatives: a patent review (2008-2012; Part 1) by Alberto Leoni, Alessandra Locatelli, Rita Morigi & Mirella Rambaldi as his Editor’s Pick for the February issue.
January 16, 2022Professor Claudiu Supuran, Editor-in-Chief of Expert Opinion on Therapeutic Patents, has chosen Tubulin inhibitors: a patent review by Yi-Min Liu , Hsiao-Ling Chen , Hsueh-Yun Lee & Jing-Ping Liou as his Editor’s Pick for the January issue.
December 18, 2013The Expert Opinion & Expert Reviews journals are now on facebook! Click here to visit our page and ‘LIKE’ us to keep updated of the newest articles and hottest news!
December 13, 2013
Five articles from the Expert Opinion Series are within the top 100 most accessed articles from the Informa healthcare journal portfolio in November 2013
December 6, 2013If you want to know more about Rho kinase inhibitors, look no further! Expert Opinion on Therapeutic Patents and Expert Opinion on Investigational Drugs have both recently posted articles on these compounds from different points of view.
December 4, 2013Editor-in-Chief of Expert Opinion on Therapeutic Patents, Prof. Claudiu Supuran, chooses Inhibitors of cathepsin G: a patent review (2005 to present) by Paulina Kosikowska & Adam Lesner as his Editor’s Pick for the December issue.
November 15, 2013Editor-in-Chief of Expert Opinion on Therapeutic Patents, Professor Claudiu Supuran, has chosen AT1 antagonists: a patent review (2008-2012) by Thomas Mavromoustakos, George Agelis & Serdar Durdagi as his Editor’s Pick for the November issue.
November 8, 2013This week in Expert Opinion, we look at the emerging treatments for some of the world’s most prevalent diseases covering: autoimmune, infectious and cardiovascular disease. Click above to find out more.
November 6, 2013Professor Claudiu Supuran, Editor in Chief of EOTP, tops the list of most cited authors in the Pharmacology and Pharmacy category.
October 8, 2013Editor-in-Chief, Prof. Claudiu Supuran, has chosen Estrogen receptor ligands: a patent review update by Ilaria Paterni, Simone Bertini, Carlotta Granchi, Marco Macchia & Filippo Minutolo as his Editor’s Pick for the October 2013 issue of Expert Opinion on Therapeutic Patents!
August 23, 2013Non-peptidic δ opioid receptor agonists and antagonists (2000 – 2012) by Hideaki Fujii, Toshihiro Takahashi and Hiroshi Nagase
July 31, 2013PDE4 inhibitors: a review of current developments (2010-2012) by Amadeu Gavaldà & Richard S Roberts
June 24, 2013
European patent for Pfizer’s Viagra expires – 21st June 2013
Despite extending the patent protection on Viagra (sildenafil) in the US until 2020, Pfizer now has to face the effects of patent expiration in the UK and other countries in Europe.
June 21, 2013
5-Lipoxygenase inhibitors: a review of recent patents (2010 – 2012) by Bettina Hofmann & Dieter Steinhilber
May 16, 2013A note from the Guest Editor, Professor Claudiu Supuran, about the Carbonic Anhydrase Inhibitors themed issue.
April 17, 2013Sigma receptor modulators: a patent review by Simona Collina, Raffaella Gaggeri, Annamaria Marra, Andrea Bassi, Sara Negrinotti, Francesca Negri & Daniela Rossi
March 15, 2013
PARP INHIBITORS IN CANCER THERAPY: AN UPDATE by Gianluca Papeo, Elena Casale, Alessia Montagnoli, and Alessandra Cirla
February 20, 2013Novel 1H-1,2,3-, 2H-1,2,3-, 1H-1,2,4- and 4H-1,2,4-triazole derivatives: a patent review (2008-2011) by Vitor F Ferreira et al
January 17, 2013Novel prostaglandin receptor modulators – Part II: EP receptor modulators; a patent review (2002 – 2012) by Daniel Flesch, Daniel Merk, Christina Lamers & Manfred Schubert-Zsilavecz is the article pick of the month from Editor-in-Chief Claudiu Supuran.
December 14, 2012Sulfatase inhibitors: a patent review by Spencer J Williams is our Editor’s pick from Claudiu T. Supuran for the January 2013 issue of Expert Opinion on Therapeutic Patents.
October 15, 2012Patented TGR5 modulators: a review (2006 – present) by Antimo Gioiello, Emiliano Rosatelli, Roberto Nuti, Antonio Macchiarulo & Roberto Pellicciari is the pick of the November issue from our Editor-in-Chief Claudiu Supuran.
September 27, 2012Flavonoids in the therapy and prophylaxis of flu: a patent review by Sônia S Costa, José Nelson S S Couceiro, Isabel Cristina V Silva, David do C Malvar, Marcela A S Coutinho, Luiza Maria M Camargo, Michelle F Muzitano & Frederico A Vanderlinde is our Editor’s pick of the month for the October issue.
August 20, 2012
Novel pharmacological modulators of autophagy and therapeutic prospects by Bischoff, Josset and Dumont is the Editor’s pick for September in EOTT.
This interesting paper reviews the scientific and patent literature of the last 4 years (2008-2012) in the field of autophagy and modulators (inhibitors or enhancers) of this phenomenon.
March 27, 2012In the interests of transparency, the editors would like to take the opportunity to update our readers on our ethical policies, and assure you that we take any breach of said policies very serieously, and will will investigate all such issues as fully as possible.
February 20, 2012
“Compositions and methods for treatment of Parkinson’s disease: a patent evaluation of WO2011/102847A1” Valerio Chiurchiù, Mauro Maccarrone, & Antonio Orlacchio
An evaluation of the application: WO2011/102847A1, which discusses novel and interesting methods to treat Parkinson’s disease (PD). The invention under discussion centres on a method for treating or preventing PD by increasing the level of at least one protein involved in an autoregulatory pathway, which is fundamental during mDA neurons differentiation.
For access to the article summary, please click here.
January 13, 2012
“Tachykinin NK2 receptor antagonists. A patent review (2006 – 2010)” Maria Altamura
In this article, Dr Maria Altamura discusses the potential of Tachykinin NK2 receptor antagonists in the treatment of various gastrointestinal, genitourinary and CNS diseases. An overview of patenting activity in the last 5 years is provided, including an evaluation of the patents novelty, proposed indications and clinical studies. Furthermore, patents claiming new therapeutic indications are included in a dedicated section.
For access to the article summary, please click here.
September 30, 2011Expert Opinion has just recorded a Podcast with Dr Patrick Gunning from the University of Toronto. Dr Gunning discussed his paper entitled ‘Signal transducer and activator of transcription 3 inhibitors: a patent review’ published in the January 2011 issue of Expert Opinion on Therapeutic Patents. Dr Gunning describes the molecular strategies that have been employed to inhibit aberrantly activated Stat3 protein activity in human cancers. Although there have been great developments in this field, no Stat3 inhibitor has yet gained FDA approval.
September 23, 2011This month, Expert Opinion has recorded a Podcast with Dr Philip Carpino from Pfizer. Dr Carpino discussed his paper entitled ‘Diabetes area participation analysis: a review of companies and targets described in the 2008 – 2010 patent literature’ published in the December 2010 issue of Expert Opinion on Therapeutic Patents. Dr Carpino describes the competitive landscape in the area and the pharmacological targets that pharmaceutical companies and academic institutions are focusing on. The pharmaceutical industry has responded to the diabetes crisis by investigating multiple targets and many different pathways and it remains to be seen if this flurry of patent activity has lead to more compounds in clinical development.